A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Condition:   Human Papillomavirus Infection Interventions:   Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli);   Biological: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine Sponsors:   Beijing Health Guard Biotechnology, Inc;   Jiangsu Province Centers for Disease Control and Prevention;   National Institutes for Food and Drug Control, China;   Nanjing Sangruisi Pharmaceutical Technology Co., Ltd;   School of Public Health of Southeastern University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials